GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipca Laboratories Ltd (BOM:524494) » Definitions » Price-to-Owner-Earnings

Ipca Laboratories (BOM:524494) Price-to-Owner-Earnings : 65.41 (As of May. 16, 2025)


View and export this data going back to 1994. Start your Free Trial

What is Ipca Laboratories Price-to-Owner-Earnings?

As of today (2025-05-16), Ipca Laboratories's share price is ₹1392.50. Ipca Laboratories's Owner Earnings per Share (TTM) ended in Mar. 2024 was ₹21.29. It's Price-to-Owner-Earnings for today is 65.41.


The historical rank and industry rank for Ipca Laboratories's Price-to-Owner-Earnings or its related term are showing as below:

BOM:524494' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 24.68   Med: 41.64   Max: 63.69
Current: 63.69

During the past 13 years, the highest Price-to-Owner-Earnings of Ipca Laboratories was 63.69. The lowest was 24.68. And the median was 41.64.


BOM:524494's Price-to-Owner-Earnings is ranked worse than
84.01% of 444 companies
in the Drug Manufacturers industry
Industry Median: 24.275 vs BOM:524494: 63.69

As of today (2025-05-16), Ipca Laboratories's share price is ₹1392.50. Ipca Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ₹28.75. Therefore, Ipca Laboratories's PE Ratio (TTM) for today is 48.43.

As of today (2025-05-16), Ipca Laboratories's share price is ₹1392.50. Ipca Laboratories's EPS without NRI for the trailing twelve months (TTM) ended in was ₹34.15. Therefore, Ipca Laboratories's PE Ratio without NRI for today is 40.78.

During the past 13 years, Ipca Laboratories's highest PE Ratio without NRI was 145.63. The lowest was 18.93. And the median was 34.45.


Ipca Laboratories Price-to-Owner-Earnings Historical Data

The historical data trend for Ipca Laboratories's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipca Laboratories Price-to-Owner-Earnings Chart

Ipca Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 48.07 24.93 40.56 37.03 58.17

Ipca Laboratories Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 58.17 - - -

Competitive Comparison of Ipca Laboratories's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ipca Laboratories's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Ipca Laboratories's Price-to-Owner-Earnings falls into.


;
;

Ipca Laboratories Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Ipca Laboratories's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1392.50/21.29
=65.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ipca Laboratories  (BOM:524494) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Ipca Laboratories Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Ipca Laboratories's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Ipca Laboratories Business Description

Traded in Other Exchanges
Address
125, Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Ipca Laboratories Ltd is a pharmaceutical company. The company's principal activity is the Development, Manufacturing, and Marketing of Pharmaceuticals Products. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), Losartan. The company has only one reportable primary business segment, pharmaceuticals.

Ipca Laboratories Headlines

No Headlines